The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast

Research Project

Project/Area Number	24K19237
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 54020:Connective tissue disease and allergy-related
Research Institution	Tokyo Medical and Dental University
Principal Investigator	LEE WENSHI 東京医科歯科大学, 大学院医歯学総合研究科, 非常勤講師 (30883590)
Project Period (FY)	2024-04-01 – 2026-03-31
Project Status	Granted (Fiscal Year 2024)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2025: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000) Fiscal Year 2024: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	miRNA-9 / rheumatoid arthritis / RasGRP4 / drug delivery system
Outline of Research at the Start	The delivery of miR-9/RasGRP4 siRNA using lactosome with cell surface receptor antibodies in osteoclasts/macrophages The effects of lactosome-miR-9/ RasGRP4 siRNA on osteoclasts/macrophages Lactosome-miR-9 mimic/ RasGRP4 siRNA in K/BxN serum transfer arthritis (STA) mice